PHMMF (Pharma Mar) Marketable Securities: $137.6 Mil (As of Mar. 2026)


PHMMF Pharma Mar SA PHMMF
82 GF Score
Price $90.90
GF Value $94.75
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Pharma Mar Marketable Securities?

Pharma Mar PHMMF -3.64% 82 Marketable Securities is $137.6 Mil as of Mar. 2026. GuruFocus rates PHMMF with a GF Score™ of 82/100 and a GF Value™ of $94.75 (Fairly Valued). The stock has 3 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Pharma Mar's Marketable Securities for the quarter that ended in Mar. 2026 was $137.6 Mil.

Pharma Mar's annual Marketable Securities declined from Dec. 2023 ($111.8 Mil) to Dec. 2024 ($95.6 Mil) but then increased from Dec. 2024 ($95.6 Mil) to Dec. 2025 ($174.9 Mil).

Pharma Mar  (OTCPK:PHMMF) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Pharma Mar Marketable Securities Related Terms

Pharma Mar Marketable Securities Historical Data

* Premium members only.

The historical data trend for Pharma Mar's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharma Mar Marketable Securities Chart

Pharma Mar Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 100.04 34.54 111.82 95.59 174.95

Pharma Mar Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 87.09 122.82 113.78 174.95 137.56
PHMMF
82GF Score
Pharma Mar SA PHMMF
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharma Mar Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $137.6 Mil mean?
Pharma Mar (PHMMF) has a Marketable Securities of $137.6 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Pharma Mar and its competitors.
Is Pharma Mar's Marketable Securities too high?
Pharma Mar's current Marketable Securities is $137.6 Mil. Overall, Pharma Mar has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pharma Mar's Marketable Securities compare to VRTX and REGN?
Pharma Mar's Marketable Securities of $137.6 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Pharma Mar and its competitors. Pharma Mar's current Marketable Securities is $137.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma Mar stock overvalued right now?
Based on GuruFocus' analysis, Pharma Mar (PHMMF) is currently considered Fairly Valued. The stock's GF Value™ is $94.75, compared to a current price of $90.90 — trading 4.1% below its estimated fair value. The current Marketable Securities is $137.6 Mil. Pharma Mar's overall GF Score™ is 82/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Pharma Mar (PHMMF), the current Marketable Securities is $137.6 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pharma Mar (PHMMF) Overvalued in 2026?

Based on GuruFocus' analysis, Pharma Mar stock appears to be undervalued. The current stock price of $90.90 is trading 4.1% below its estimated GF Value™ of $94.75. GuruFocus considers Pharma Mar to be Fairly Valued.

Key valuation signals for PHMMF:

  • Marketable Securities: $137.6 Mil
  • GF Value™: $94.75 vs. price of $90.90 (4.1% below fair value)
  • GF Score™: 82/100 with 3 warning signs

No single metric tells the full story. See the PHMMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pharma Mar Business Description

Address Avenida de los Reyes, 1, Poligono Industrial La Mina-norte, Colmenar Viejo, Madrid, ESP, 28770
Pharma Mar SA is engaged in the research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It also produces and markets insecticides and air fresheners for household use, household products, wood treatment and decoration products, paints, and similar products. Its operating business segments are Oncology and RNAi. The company obtains its revenues from two main areas: biopharmaceuticals and consumer chemicals, but the biopharmaceuticals is the main line of business.
82GF Score

Get the complete analysis for PHMMF

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$90.90
Price
$94.75
GF Value